What alternative antifungal agents can be used instead of voriconazole?

Alternative Antifungal Agents to Voriconazole

The best alternatives to voriconazole depend on the specific fungal infection, but for invasive aspergillosis, isavuconazole or liposomal amphotericin B are preferred first-line alternatives, while for invasive candidiasis, echinocandins (caspofungin, micafungin, or anidulafungin) or fluconazole are the primary options.

For Invasive Aspergillosis

Primary Alternatives

Isavuconazole is now recognized as an equivalent first-line alternative to voriconazole for invasive pulmonary aspergillosis 1. It offers comparable efficacy with more predictable pharmacokinetics and a more favorable toxicity profile, particularly avoiding the visual disturbances and photosensitivity associated with voriconazole.

Liposomal amphotericin B (3-5 mg/kg daily) is another strong alternative, particularly recommended when azole therapy is contraindicated or in settings with high triazole resistance 1, 2. While effective, it is considered less attractive than newer triazoles due to its toxicity profile and need for intravenous administration.

Secondary Alternatives

Posaconazole represents another viable option, with recent evidence showing non-inferiority to voriconazole 3. The extended-release tablet or intravenous formulations (300 mg twice daily on day 1, then 300 mg daily) provide improved bioavailability compared to the oral suspension 2.

Itraconazole (200 mg twice daily with therapeutic drug monitoring) can be used but is generally considered less optimal than the newer triazoles 1, 4. A recent head-to-head trial showed itraconazole was not inferior to voriconazole for chronic pulmonary aspergillosis, though voriconazole had more adverse events 4.

Important Caveats for Aspergillosis Treatment

• Echinocandins alone are NOT recommended as primary therapy for invasive aspergillosis 1. They can only be used when both azoles and polyenes are contraindicated, or as part of combination therapy in select severe cases.
• Therapeutic drug monitoring is essential for all azoles (itraconazole, voriconazole, posaconazole) to optimize efficacy and minimize toxicity 1.
• Treatment duration should be minimum 6-12 weeks, depending on immunosuppression degree and clinical response 1.

For Invasive Candidiasis/Candidemia

Primary Alternatives

Echinocandins are the preferred first-line agents for most patients with candidemia, particularly those who are critically ill or have recent azole exposure 5:

• Caspofungin: 70 mg loading dose, then 50 mg daily
• Micafungin: 100 mg daily
• Anidulafungin: 200 mg loading dose, then 100 mg daily

Fluconazole (800 mg loading dose, then 400 mg daily) is an acceptable alternative for less critically ill patients without recent azole exposure and when fluconazole-susceptible species (e.g., C. albicans) are suspected 5.

Species-Specific Considerations

• For C. glabrata: Echinocandins are strongly preferred over azoles 5. Only transition to fluconazole (800 mg daily) or voriconazole if susceptibility is confirmed.
• For C. parapsilosis: Fluconazole is preferred over echinocandins due to higher MICs with echinocandins 5.
• For C. krusei: Use echinocandins, liposomal amphotericin B, or voriconazole (as C. krusei is intrinsically fluconazole-resistant) 5.

Amphotericin B Formulations

Lipid formulations of amphotericin B (3-5 mg/kg daily) are reasonable alternatives when there is intolerance, limited availability, or resistance to other agents 5. Amphotericin B deoxycholate (0.5-1.0 mg/kg daily) can be used but is less preferred due to toxicity.

For Oropharyngeal/Esophageal Candidiasis

Fluconazole (100-400 mg daily for 7-21 days depending on severity) remains the primary systemic treatment 5.

For fluconazole-refractory disease:

• Itraconazole solution (200 mg daily)
• Posaconazole suspension (400 mg twice daily for 3 days, then 400 mg daily)
• Voriconazole (200 mg twice daily) 5

For severe refractory cases requiring IV therapy:

• Echinocandins (micafungin 150 mg daily, caspofungin 70 mg loading then 50 mg daily, or anidulafungin 200 mg loading then 100 mg daily)
• Amphotericin B deoxycholate (0.3-0.7 mg/kg daily) 5

Key Clinical Pearls

• Always obtain susceptibility testing for bloodstream and clinically relevant Candida isolates to guide therapy 5.
• De-escalation strategy: Transition from echinocandins to fluconazole after 5-7 days is appropriate for stable patients with susceptible isolates and negative repeat cultures 5.
• Drug interactions: All azoles have significant CYP450 interactions requiring careful monitoring, particularly with immunosuppressants (cyclosporine, tacrolimus, sirolimus) 6, 1.
• In settings with >10% environmental triazole resistance, consider initial combination therapy (azole plus echinocandin) for invasive aspergillosis 7.